<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182815</url>
  </required_header>
  <id_info>
    <org_study_id>19-BR-0001</org_study_id>
    <nct_id>NCT04182815</nct_id>
  </id_info>
  <brief_title>Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung</brief_title>
  <acronym>TARGET</acronym>
  <official_title>Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auris Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auris Health, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate clinical safety and diagnostic accuracy of the
      robotic-assisted bronchoscopy with biopsy performed with the Monarch™ Endoscopy Platform in a
      broad range of patients with pulmonary lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite technological advancements in guided bronchoscopy such as electromagnetic navigation
      bronchoscopy and radial probe endobronchial ultrasound, successful biopsy of peripheral
      pulmonary lesions remains a challenge due to a number of factors, one of which may be the
      ability to gain access to peripheral lesions due to the size and maneuverability of
      conventional bronchoscopes. The diagnostic yield of conventional bronchoscopic approaches for
      peripheral lesions remains suboptimal.

      A novel robotic assisted bronchoscopy procedure now exists for patients with lung nodules.
      This procedure is performed using the Monarch™ platform (Auris Health, Inc., Redwood City,
      CA). This study is expected to enroll up to 1200 patients at up to 30 investigative sites.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of device or procedure related complications</measure>
    <time_frame>up to 7 days post procedure</time_frame>
    <description>The primary endpoint is a composite that includes pneumothorax requiring intervention rated as &gt; Grade 1 according to the Common Terminology Criteria for Adverse Events (CTCAE) scale, bleeding requiring medical intervention, rated as &gt; Grade 1 according to the CTCAE scale, and respiratory failure, rated as &gt; Grade 3 according to the CTCAE scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of device or procedure related complications</measure>
    <time_frame>up to 7 days post procedure</time_frame>
    <description>Individual components of the primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all pneumothoraxes</measure>
    <time_frame>up to 7 days post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure time</measure>
    <time_frame>During the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of conversion to conventional bronchoscopic procedure</measure>
    <time_frame>During the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events unrelated to device or procedure</measure>
    <time_frame>up to 7 days post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage at diagnosis</measure>
    <time_frame>up to 24 months post procedure</time_frame>
    <description>Stage at diagnosis (if applicable) will be evaluated for all robotic-assisted bronchoscopy procedures performed for suspicion of lung cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic yield</measure>
    <time_frame>up to 24 months post procedure</time_frame>
    <description>Diagnostic yield for all robotic-assisted procedure performed for suspicion of lung cancer will be evaluated based on histopathological assessment of acquired tissue samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity for malignancy</measure>
    <time_frame>up to 24 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>up to 24 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value</measure>
    <time_frame>up to 24 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value</measure>
    <time_frame>up to 24 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of post-bronchoscopy infections</measure>
    <time_frame>up to 7 days post-procedure</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Pulmonary Nodule</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Robotic assisted bronchoscopy</arm_group_label>
    <description>Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Robotic assisted bronchoscopy</intervention_name>
    <description>Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.</description>
    <arm_group_label>Robotic assisted bronchoscopy</arm_group_label>
    <other_name>Robotic assisted bronchoscopy with Monarch platform</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with indeterminate pulmonary nodules considered to undergo a bronchoscopy
        procedure per standard of care.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Over 21 years of age;

          2. Capable and willing to give informed consent;

          3. Acceptable candidate for an elective, non-emergent bronchoscopic procedure;

          4. Lung lesions, 8 mm to 50 mm in size, requiring bronchoscopic diagnosis which were
             identified on thin slice CT scan within 14 days of the intended bronchoscopy

        Exclusion Criteria:

          1. Medical contraindication to bronchoscopy as assessed by the investigator

          2. Presence of uncorrectable bleeding disorders

          3. Medical devices interfering with electro-magnetic navigation, including but not
             limited to pacemaker

          4. Patients with the target lesion having endobronchial involvement seen on chest CT

          5. Lack fitness to undergo flexible bronchoscopy as determined by the bronchoscopist
             prior to procedure,

          6. Participation in any other clinical trial within 30 days of enrollment that would
             interfere with this study;

          7. Uncontrolled or irreversible coagulopathy;

          8. Female subjects who are pregnant or nursing at the time of the procedure or those of
             child-bearing potential refusing a pregnancy test prior to the procedure;

          9. CT scan done greater than 14 days before the bronchoscopy procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Septimiu Murgu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Rehage</last_name>
    <phone>6508370301</phone>
    <phone_ext>6508370301</phone_ext>
    <email>scott.rehage@aurishealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emir Deljkich</last_name>
    <phone>6503972677</phone>
    <phone_ext>6503972677</phone_ext>
    <email>emir.deljkich@aurisrobotics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Bradley</last_name>
    </contact>
    <investigator>
      <last_name>Paul Chomiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candace Murphy</last_name>
    </contact>
    <investigator>
      <last_name>Septimiu Murgu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Lung Center, Ltd</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Buffi Moss</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan T Hovda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faye Biggs</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Nader, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Central PA</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Edevane</last_name>
    </contact>
    <investigator>
      <last_name>Sandeep Bansal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center, Hamot</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Henry</last_name>
    </contact>
    <investigator>
      <last_name>Christopher Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abby Wenzel</last_name>
    </contact>
    <investigator>
      <last_name>Nicholas Pastis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bronchoscopy</keyword>
  <keyword>Robotic bronchoscopy</keyword>
  <keyword>Lung Lesions</keyword>
  <keyword>Peripheral lesions</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Monarch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

